Jonathan A. Harris



Client Testimonials

"Since transferring our IP matters to Jonathan from an AMLaw25 law firm over three years ago, we could not be happier. He is incredibly smart, personable, and practical."
-CEO, therapeutics start-up

"His understanding of the start-up world and his business acumen are extremely strong." -General Counsel, therapeutics start-up

"His practical advice has saved us time and time again, not only monetarily, but also by avoiding the many potential pitfalls of legal nuance at the most critical stages of foundational corporate development." -President, therapeutics start-up

"Jonathan is one of a few outside patent lawyers who fully grasps the complex regulatory regime for pharmaceuticals ... his experience with both patent prosecution and patent litigation provides a unique 360° view."

-Senior Patent Counsel, big pharma

"Great in the courtroom, articulate, and quick on his feet."

-Senior Patent Counsel, big pharma

Notable Experience and Client Impact

Life Science Agreements

- Patent licenses, collaborations, and commercial agreements: bioMérieux (clinical trial agreements);
 CoRISMA (medical device) in collaboration with China Grand; Insud Pharma (commercial agreements);
 Notable (cancer therapeutic) in worldwide collaboration with OncoHeroes; VeraDermics (derm therapeutics) in multiple collaborations and manufacturing agreements
- University licenses: Cellinfinity (cancer therapeutic) with Ivy League university; Insud Pharma (diagnostic biomarkers) with Canadian university; LeptoX with Ivy League University; VeraDermics with Ivy League university

Patent Litigation

- Analyze patent portfolios in preparation for Paragraph IV Notice Letters and litigation
- Served as first chair trial counsel in numerous Paragraph IV patent actions: Cialis® (\$2.3 billion annual sales); Lyrica® (\$5.1 billion annual sales); Oxycontin® (\$1.8 billion annual sales), Reclast®/Zometa® (\$1.5 billion annual sales), and Ritalin®/Focalin® (\$450 million annual sales)

IP Due Diligence

Oversee IP diligence on small and large molecule therapeutics: Abraxane® (\$1B annual sales), Eliquis® (\$8B annual sales), Suboxone® (\$1.1B annual sales), Tysabri® (\$1.9B annual sales), and clinical trial assets in Phase I, II and III.

Patent Preparation, Prosecution, Counseling

• Prepare and prosecute over 200 patent applications. Retained to oversee independent law firm's prosecution of Orange Book listable patents. Assess patentability, conduct freedom to operate, and prepare patent opinions.



Jonathan A. Harris
Partner, Intellectual Property
E jaharris@nutter.com
P 617.439.2422